Gossamer Bio Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutics in immunology, inflammation, and oncology. It centers its efforts on seralutinib, an investigational inhaled inhibitor of PDGFRα/β, CSF1R, and c-KIT, delivered via dry powder inhaler for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). This targets rare, serious respiratory conditions with limited options, aiming to improve patient outcomes through innovative delivery that enhances lung-specific efficacy while minimizing systemic exposure. Previously, the company advanced candidates like GB001 for moderate-to-severe eosinophilic asthma and allergic conditions, underscoring its expertise in these therapeutic areas. Gossamer Bio Inc. operates within the health technology sector, specifically pharmaceuticals, contributing to advancements in precision medicine for cardiopulmonary diseases. Founded in 2015 and headquartered in San Diego, California, it plays a key role in the biopharma landscape by advancing clinical-stage assets toward potential commercialization.